[go: up one dir, main page]

UA97813C2 - Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола - Google Patents

Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола Download PDF

Info

Publication number
UA97813C2
UA97813C2 UAA200904218A UAA200904218A UA97813C2 UA 97813 C2 UA97813 C2 UA 97813C2 UA A200904218 A UAA200904218 A UA A200904218A UA A200904218 A UAA200904218 A UA A200904218A UA 97813 C2 UA97813 C2 UA 97813C2
Authority
UA
Ukraine
Prior art keywords
peg
alpha
beta
castor oil
methoxy
Prior art date
Application number
UAA200904218A
Other languages
English (en)
Ukrainian (uk)
Inventor
Жан Франсуа Александр Лукас Эги
Вим Альберт Алекс Элтерман
Йоланда Лидия Ланг
Сигрид Карл Мария Стокбрукс
Карина Лейс
Ремоортере Петер Йозеф Мария ван
Анна Фор
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97813(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA97813C2 publication Critical patent/UA97813C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение касается фумаратной соли (альфа S, бета R)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола, фармацевтических композиций, которые содержат как активный ингредиент указанную соль, и способов их получения.
UAA200904218A 2006-12-05 2007-03-12 Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола UA97813C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
UA97813C2 true UA97813C2 (ru) 2012-03-26

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904218A UA97813C2 (ru) 2006-12-05 2007-03-12 Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола

Country Status (34)

Country Link
US (1) US8546428B2 (ru)
EP (1) EP2086940B1 (ru)
JP (2) JP2010511663A (ru)
KR (1) KR101514700B1 (ru)
CN (2) CN101547904A (ru)
AP (1) AP2498A (ru)
AR (1) AR064149A1 (ru)
AU (1) AU2007328945B2 (ru)
BR (1) BRPI0719693A2 (ru)
CA (1) CA2668512C (ru)
CL (1) CL2007003472A1 (ru)
CY (1) CY1113594T1 (ru)
DK (1) DK2086940T3 (ru)
EA (1) EA017091B9 (ru)
ES (1) ES2387923T3 (ru)
HK (1) HK1214513A1 (ru)
HR (1) HRP20120639T1 (ru)
IL (1) IL199077A (ru)
JO (1) JO2973B1 (ru)
ME (1) ME01456B (ru)
MX (1) MX2009005909A (ru)
MY (1) MY148844A (ru)
NO (1) NO342773B1 (ru)
NZ (1) NZ576485A (ru)
PE (1) PE20081350A1 (ru)
PL (1) PL2086940T3 (ru)
PT (1) PT2086940E (ru)
RS (1) RS52408B (ru)
SI (1) SI2086940T1 (ru)
TW (1) TWI417098B (ru)
UA (1) UA97813C2 (ru)
UY (1) UY30762A1 (ru)
WO (1) WO2008068231A1 (ru)
ZA (1) ZA200903907B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
US20180000810A1 (en) * 2015-01-27 2018-01-04 Janssen Pharmaceutica Nv Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
US10196360B2 (en) 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
SMT202100723T1 (it) * 2016-07-20 2022-01-10 Novartis Ag Derivati di amminopiridina e loro uso come inibitori selettivi di alk-2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
LT3943070T (lt) 2017-07-14 2024-02-12 Janssen Pharmaceutica Nv Ilgo veikimo bedakvilino preparatai
WO2020123336A1 (en) * 2018-12-13 2020-06-18 Qrumpharma Inc. Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
CN113271930A (zh) 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
EP4243800A1 (en) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
CA2270123A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
IL122025A (en) * 1996-10-30 2003-01-12 Lilly Co Eli Use of raloxifene or pharmaceutically acceptable salts or solvates thereof, in the preparation of a medicament for preventing breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
ATE463482T1 (de) * 2002-07-25 2010-04-15 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ATE390925T1 (de) * 2004-05-28 2008-04-15 Janssen Pharmaceutica Nv Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
CA2577273C (en) * 2004-09-02 2013-11-19 Janssen Pharmaceutica N.V. Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법

Also Published As

Publication number Publication date
AU2007328945A1 (en) 2008-06-12
DK2086940T3 (da) 2012-08-20
PL2086940T3 (pl) 2012-10-31
NZ576485A (en) 2012-01-12
KR20090087020A (ko) 2009-08-14
NO20092535L (no) 2009-08-06
US8546428B2 (en) 2013-10-01
JO2973B1 (en) 2016-03-15
HK1214513A1 (zh) 2016-07-29
IL199077A (en) 2016-09-29
CN101547904A (zh) 2009-09-30
EA017091B1 (ru) 2012-09-28
AU2007328945B2 (en) 2014-04-03
ME01456B (me) 2014-04-20
CY1113594T1 (el) 2016-06-22
SI2086940T1 (sl) 2012-09-28
ES2387923T3 (es) 2012-10-04
WO2008068231A1 (en) 2008-06-12
EP2086940A1 (en) 2009-08-12
BRPI0719693A2 (pt) 2013-12-24
UY30762A1 (es) 2008-07-03
JP5894239B2 (ja) 2016-03-23
CN105012303A (zh) 2015-11-04
US20100028428A1 (en) 2010-02-04
MX2009005909A (es) 2009-06-16
HRP20120639T1 (hr) 2012-08-31
JP2015028049A (ja) 2015-02-12
EA200970532A1 (ru) 2009-10-30
KR101514700B1 (ko) 2015-04-24
EA017091B9 (ru) 2014-10-30
PT2086940E (pt) 2012-08-09
EP2086940B1 (en) 2012-05-16
TWI417098B (zh) 2013-12-01
AP2498A (en) 2012-10-19
CA2668512A1 (en) 2008-06-12
ZA200903907B (en) 2013-08-28
CL2007003472A1 (es) 2008-08-22
JP2010511663A (ja) 2010-04-15
MY148844A (en) 2013-06-14
NO342773B1 (no) 2018-08-06
TW200838527A (en) 2008-10-01
AR064149A1 (es) 2009-03-18
PE20081350A1 (es) 2008-09-18
RS52408B (sr) 2013-02-28
AP2009004870A0 (en) 2009-06-30
CA2668512C (en) 2015-03-24

Similar Documents

Publication Publication Date Title
UA97813C2 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
AU2021204135B2 (en) Dispersible compositions
EP2623100A1 (en) Preparation for improving solubility of poorly soluble drug
EA013686B1 (ru) Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
KR101503559B1 (ko) 경구 분립상 항종양제
JPWO2019130749A1 (ja) 新規微粒子コーティング（薬物含有中空粒子及びその製法）
US20230390302A1 (en) Pharmaceutical formulation
CN107693516B (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
CN102048738A (zh) 含有环嘧耐平药用复合物的药物组合物制剂
US20250195417A1 (en) Additive composition for orally disintegrating tablet
CA2973301C (en) Dispersible compositions comprising bedaquiline fumarate
HK40101645A (en) Dispersible compositions
EA042247B1 (ru) Диспергируемые композиции